Abstract
Several reports indicated that aberrant miR-1826 was involved in the initiation and progression of malignancies. However, the clinical significance of miR-1826 in human colorectal cancer (CRC) has not been addressed. The aim of this study was to evaluate the expression and clinical significance of miR-1826 in CRC. We detected miR-1826 expressions by quantitative realtime PCR (qRT-PCR) in 72 CRC tissues, adjacent nontumor tissues (NATs) and five CRC cell lines, and found that miR-1826 expression in CRC tissues was higher than that in NATs (p<0.05). High miR-1826 expression was significantly associated with some clinicopathologic features such as regional lymph node metastasis (p=0.018), advanced TNM clinical stage (p=0.004), which led to a poor overall survival rate in CRC patients (p=0.032). Our further studies in vitro also demonstrated that miR-1826 inhibitor could effectively suppress the cell proliferation, promote apoptosis and induce G0/G1 cell cycle arrest in CRC cells (p<0.05). Meanwhile, the abilities of cell invasion and migration were effectively suppressed by miR-1826 inhibitor (p<0.05). These findings strongly suggested that miR-1826 played a critical role in the initiation and progression of CRC. Up-regulation of miR-1826 might serve as a novel prognostic marker of CRC and could be a potential target for CRC therapies.
Keywords: Biomarker, colorectal cancer, miR-1826, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Volume: 16 Issue: 9
Author(s): You Hu, Bin Yi, Songbing He, Ling Gao, Pengfei Liu, Lei Wang, Jing Yu, Daiwei Wan, Jin Zhou, Xinguo Zhu and Qiaoming Zhi
Affiliation:
Keywords: Biomarker, colorectal cancer, miR-1826, prognosis.
Abstract: Several reports indicated that aberrant miR-1826 was involved in the initiation and progression of malignancies. However, the clinical significance of miR-1826 in human colorectal cancer (CRC) has not been addressed. The aim of this study was to evaluate the expression and clinical significance of miR-1826 in CRC. We detected miR-1826 expressions by quantitative realtime PCR (qRT-PCR) in 72 CRC tissues, adjacent nontumor tissues (NATs) and five CRC cell lines, and found that miR-1826 expression in CRC tissues was higher than that in NATs (p<0.05). High miR-1826 expression was significantly associated with some clinicopathologic features such as regional lymph node metastasis (p=0.018), advanced TNM clinical stage (p=0.004), which led to a poor overall survival rate in CRC patients (p=0.032). Our further studies in vitro also demonstrated that miR-1826 inhibitor could effectively suppress the cell proliferation, promote apoptosis and induce G0/G1 cell cycle arrest in CRC cells (p<0.05). Meanwhile, the abilities of cell invasion and migration were effectively suppressed by miR-1826 inhibitor (p<0.05). These findings strongly suggested that miR-1826 played a critical role in the initiation and progression of CRC. Up-regulation of miR-1826 might serve as a novel prognostic marker of CRC and could be a potential target for CRC therapies.
Export Options
About this article
Cite this article as:
Hu You, Yi Bin, He Songbing, Gao Ling, Liu Pengfei, Wang Lei, Yu Jing, Wan Daiwei, Zhou Jin, Zhu Xinguo and Zhi Qiaoming, Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1871520615666150507122434
DOI https://dx.doi.org/10.2174/1871520615666150507122434 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Current Drug Targets Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeted Drug Delivery to Cancer Stem Cells through Nanotechnological Approaches
Current Stem Cell Research & Therapy Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
CNS & Neurological Disorders - Drug Targets Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Dual Role of microRNAs in Autophagy of Colorectal Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Fe-S Proteins Acting as Redox Switch: New Key Actors of Cellular Adaptive Responses
Current Chemical Biology Oxaliplatin-Induced Lung Toxicity. Case Report and Review of the Literature
Current Drug Safety Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry 3, 3′-Dimethylquercetin Inhibits the Proliferation of Human Colon Cancer RKO Cells through Inducing G2/M Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Rationale and Design of the CAN Study: an RCT of Survival after Propofol- or Sevoflurane-based Anesthesia for Cancer Surgery
Current Pharmaceutical Design Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Identification of HDACs Inhibitor E14 Metabolites Appeared in Rat Plasma, Feces and Urine by UPLC-QTOF-MS/MS
Current Pharmaceutical Analysis